This inventor holds 1 USPTO granted patent and 2 published patent applications and 2 EPO patents. Top assignee: Universitetet I Oslo. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Ludvig Munthe: Innovator in Cancer Treatment
Introduction
Ludvig Munthe is a notable inventor based in Fjellhamar, Norway. He has made significant contributions to the field of cancer treatment through his innovative research and patents. His work focuses on developing therapies for ALK-negative cancers, which are often challenging to treat.
Latest Patents
Munthe holds a patent for "ALK inhibitors for treatment of ALK-negative cancer and plasma cell-mediated diseases." This invention provides a method for treating ALK-negative/LTK-positive cancer by administering a pharmaceutically effective dose of a linear inhibitor of ALK. The invention is particularly useful in treating multiple myeloma, including cases that are resistant to proteasome inhibitors. He has 1 patent to his name.
Career Highlights
Ludvig Munthe is affiliated with the University of Oslo, where he conducts his research. His work has garnered attention for its potential to improve treatment outcomes for patients suffering from difficult-to-treat cancers. His dedication to advancing medical science is evident in his innovative approaches to cancer therapy.
Collaborations
Munthe collaborates with esteemed colleagues such as Hesso Farhan and Kjetil Tasken. Their combined expertise contributes to the advancement of research in cancer treatment and enhances the impact of their findings.
Conclusion
Ludvig Munthe is a pioneering inventor whose work in developing ALK inhibitors represents a significant advancement in cancer treatment. His contributions to medical science continue to inspire and pave the way for future innovations in the field.